Organization | George Papanicolaou Hospital

George Papanicolaou Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Thessaloniki Greece (2010)

Organization Overview

First Clinical Trial

2010

NCT00336362

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

George Papanicolaou Hospital | "G. Papanikolaou" General Hospital, Thessaloniki, Greece

Active Ingredients

Drugs in Phase 3 Trials (4)

dexmedetomidine (precedex) (2 trials)

esmolol (brevibloc) (2 trials)

propofol (diprivan) (1 trial)

sevoflurane (ultane) (1 trial)

Drugs in Phase 2 Trials (3)

coronavirus-specific t cell (cst) (1 trial)

pentavalent-specific t cells (penta-sts) (1 trial)

platelet-rich plasma (1 trial)

Drugs in Other Trials (4)

hyaluronic acid (1 trial)

hydroxyurea (hydrea) (1 trial)

oxygen (2 trials)

plerixafor (mozobil) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Aneurysm (Phase 3)

Brain Neoplasms (Phase 3)

Cerebral Arterial Diseases (Phase 3)

Intracranial Aneurysm (Phase 3)

Tennis Elbow (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial APIs: 11